Ascidian and Lilly Enter Global Research Collaboration to Develop RNA Exon Editors for Devastating Kidney Diseases

/PRNewswire/ — Ascidian Therapeutics, a biotechnology company seeking to treat human diseases by rewriting RNA, today announced a global research…Read More